TMS Therapy Validated for Poststroke Bladder Dysfunction

Researchers report that repetitive TMS targeting the motor cortex reduces urinary urgency and frequency in stroke survivors with overactive bladder. The therapy works by modulating neural pathways disrupted by stroke, restoring bladder control. Patients experienced a 40% decrease in incontinence episodes over 12 weeks.

Safety analysis found no serious side effects, with only mild transient headaches reported. This positions TMS as a viable alternative to medications that often cause cognitive or cardiovascular side effects in elderly patients. The therapy's non-invasive nature also reduces infection risk compared to catheter-based interventions.

These findings challenge current treatment hierarchies that rely on anticholinergic drugs or invasive procedures. TMS offers a scalable, low-risk option for the estimated 40% of stroke survivors suffering from bladder dysfunction. Integration into rehabilitation programs could accelerate recovery and improve quality of life.

Power Move: TMS is poised to disrupt the $2B neurogenic bladder market by offering a drug-free, non-invasive solution. Early adoption by stroke rehabilitation centers will create a competitive advantage in patient outcomes and cost reduction.

This article was edited with AI assistance for readability. Read original here.